Clinical trials: Female Breast Neoplasms
Healthy
Flaxseed Intervention Study to Assess Sex Hormone Levels Among Post-Menopausal Women
The purpose of this study is to understand whether consuming flaxseed for approximately 50 days may beneficially affect the level of certain hormones in the blood thought to be involved in the development of breast cancer.
- Trial name
- NCT02501031
- Testing
- Ground flaxseed
- Where
- Canada
- Volunteers
- 99 people, healthy volunteers welcome
- Sponsor
- Cancer Care Ontario
Pain, Neuropathic, Epilepsy
Cancer in Patients With Gabapentin (GPRD)
High doses of gabapentin are associated with pancreatic acinar cell tumors in rats, but there has been no post marketing pancreatic carcinogenicity signal with gabapentin as reported by spontaneous reports in AERS or in the…
- Conditions
- Pain, Neuropathic, Epilepsy, Renal Pelvis Cancer, Pancreatic Cancer
- Trial name
- NCT01236053
- Testing
- Gabapentin prescriptions
- Volunteers
- 2,323,608 people
- Sponsor
- GlaxoSmithKline
Breast Cancer
Neoadjuvant or Adjuvant Epirubicin, Cyclophosphamide, and Paclitaxel in Treating Women With Stage I, Stage II, or Stage III Breast Cancer
RATIONALE: Drugs used in chemotherapy, such as epirubicin, cyclophosphamide, and paclitaxel, use different ways to stop tumor cells from dividing so they stop growing or die.
- Trial name
- NCT00072319
- Testing
- filgrastim, cyclophosphamide, epirubicin hydrochloride
- Where
- United States
- Sponsor
- Memorial Sloan Kettering Cancer Center
Breast Cancer
Doxorubicin in Treating Women With Advanced Breast Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Giving drugs in different forms may kill more tumor cells.
- Trial name
- NCT00003165
- Testing
- doxorubicin-HPMA conjugate
- Where
- 6 sites in United Kingdom
- Volunteers
- 25 people
- Sponsor
- University of Glasgow
Breast Cancer Female
21DIF039: Prone to Supine Breast MRI II, P2S2 Breast MRI Trial
The purpose of this study is to determine whether a supine breast MRI obtained with a second intravenous injection of gadolinium contrast immediately after a standard clinical prone breast MRI will provide sufficient tumor…
- Trial name
- 21DIF039 (NCT05131607)
- Testing
- Supine MRI
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- Dartmouth-Hitchcock Medical Center
Breast Cancer
Study of Vitamin D for Premenopausal Women at High Risk for Breast Cancer
This proposal is for a pilot study of 20 premenopausal women at high risk for breast cancer development who will receive high dose vitamin D3, cholecalciferol 20,000 IU (2 capsules) weekly, or 30,000 IU (3 capsules) weekly, for 1…
- Trial name
- NCT00976339
- Testing
- Cholecalciferol
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Katherine D. Crew
Quality of Life, Breast Neoplasm Female
QOL of Women With HR-Positive Metastatic BC Treated in the First-line Setting: Comparison Between Public and Private Institutions.
Assess the quality of life in patients with hormone receptor positive, human epidermal growth factor receptor-type 2 negative metastatic breast cancer treated in first line (patients with new metastasis or recurrence during…
- Trial name
- BRAVE (NCT05287139)
- Testing
- Quality of Life
- Where
- Brazil
- Volunteers
- 202 people
- Sponsor
- Beneficência Portuguesa de São Paulo
Breast Cancer
Combination Chemotherapy in Treating Older Women With Metastatic Breast Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one chemotherapy drug may kill more tumor cells.
- Trial name
- NCT00010075
- Testing
- fluorouracil, leucovorin calcium, mitoxantrone hydrochloride
- Where
- 6 sites in France
- Sponsor
- GERCOR - Multidisciplinary Oncology Cooperative Group
Breast Disease, Benign Breast Disease
Effectiveness Validation of CELBREA® in Symptomatic Women or With Diagnostic Doubt of Breast Pathology (DETECT-BH)
This is an observational, prospective, and transversal study, designed to evaluate the effectiveness of CELBREA® in women from the local community coming to consult at the Breast Pathology Unit of La Paz Hospital (Madrid, Spain)…
- Conditions
- Breast Disease, Benign Breast Disease, Breast Cancer
- Trial name
- DETECT-BH (NCT05857111)
- Testing
- Celbrea
- Where
- Spain
- Volunteers
- 255 people
- Sponsor
- Jose Ignacio Sánchez
Breast Cancer, Corpus Uteri Cancer
INtegrating Systematic PatIent-Reported Evaluations in Multi-Disciplinary Tumor Boards: The INSPIRE Study
The purpose of the study is to characterize baseline multidisciplinary tumor board (MDTB) context and variability, evaluate the relationship between baseline fitness of patients with cancer and initial treatment recommendations…
- Conditions
- Breast Cancer, Corpus Uteri Cancer, Ovary Cancer, Pancreas Cancer
- Trial name
- INSPIRE (NCT07671937)
- Testing
- INSPIRE (INtegrating Systematic PatIent-Reported Evaluations), Capture of patient-reported outcomes, Enhanced Clinician Awareness
- Where
- 3 sites in United States
- Volunteers
- 2,748 people
- Sponsor
- University of Alabama at Birmingham
brca1 Mutation Carrier, brca2 Mutation Carrier
Rucaparib(CO-338;Formally Called AG-014699 or PF-0136738) in Treating Patients With Locally Advanced or Metastatic Breast Cancer or Advanced Ovarian Cancer
RATIONALE: rucaparib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. PURPOSE: This phase II trial is studying the side effects and best dose of rucaparib and to see how well it works in…
- Conditions
- brca1 Mutation Carrier, brca2 Mutation Carrier, Breast Cancer, Ovarian Cancer
- Trial name
- NCT00664781
- Testing
- rucaparib (CO-338; formally AG-014699 or PF-01367338), protein expression analysis, western blotting
- Where
- 7 sites in United Kingdom
- Volunteers
- 78 people
- Sponsor
- Cancer Research UK
Advanced Solid Tumors Cancer
A Study Evaluating the Safety, Pharmacokinetics and Anti-Tumor Activity of ABBV-176 in Subjects With Advanced Solid Tumors Likely to Express Prolactin Receptor (PRLR)
This is an open-label, Phase I, dose-escalation study to determine the maximum tolerated dose (MTD) and the recommended phase two dose (RPTD), and to assess the safety, preliminary efficacy, and pharmacokinetic (PK) profile of…
- Trial name
- NCT03145909
- Testing
- ABBV-176
- Where
- 11 sites in United States, Australia and 2 more
- Volunteers
- 19 people
- Sponsor
- AbbVie
Breast Cancer
Docetaxel and Cyclophosphamide Compared to Anthracycline-Based Chemotherapy in Treating Women With HER2-Negative Breast Cancer
RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of breast cancer cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT01547741
- Testing
- Doxorubicin, Cyclophosphamide, Docetaxel
- Where
- 915 sites in United States, Puerto Rico
- Volunteers
- 4,242 people
- Sponsor
- NSABP Foundation Inc
Advanced Solid Tumor, HR+/HER2- Breast Cancer
Study of AVZO-021 in Patients With Advanced Solid Tumors
This study, the first clinical trial of AVZO-021, aims to determine the safety, tolerability, pharmacokinetics, pharmacodynamics, maximum tolerated dose, and anti-tumor effects of AVZO-021 in patients with advanced solid tumors.
- Conditions
- Advanced Solid Tumor, HR+/HER2- Breast Cancer, HR+, HER2-, Advanced Breast Cancer, CCNE1 Amplification
- Trial name
- NCT05867251
- Testing
- AVZO-021, Palbociclib, Fulvestrant
- Where
- 13 sites in United States, Australia
- Volunteers
- 430 people
- Sponsor
- Avenzo Therapeutics, Inc.
Breast Cancer, Ovarian Cancer
Removal of the Ovaries/Fallopian Tubes and CA-125 Screening to Reduce the Risk of Ovarian Cancer in Women at Increased Genetic Risk
This study will evaluate women who are at increased genetic risk of developing ovarian cancer because they or a close relative have a mutation in the BRCA1 or BRCA2 gene (the genes that cause most of the genetic forms of ovarian…
- Trial name
- NCT00043472
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- National Cancer Institute (NCI)
Breast Cancer
Effect of Counseling on Psychological Stress Amongst Women Felt to be at High Risk for Breast Cancer Development
To evaluate 1) the extent of patient overestimation of breast cancer development risk in subjects referred to a physician-based high-risk breast clinic; 2) the ability of physician counseling to improve patient risk perception…
- Trial name
- NCT00381927
- Testing
- Physician Counseling
- Where
- United States
- Volunteers
- 80 people
- Sponsor
- Baystate Medical Center
Female Breast Cancer, Depression
An Intervention for Female Breast CANcer: Acceptance and Commitment Therapy (I-CAN-ACT) for Depression and Physical Pain
As a result of the cancer diagnosis and medical therapies, women with breast cancer often encounter debilitating cooccurring psychological and physical symptoms.
- Conditions
- Female Breast Cancer, Depression, Pain
- Trial name
- I-CAN-ACT (NCT05374161)
- Testing
- Acceptance and Commitment Therapy, Waitlist Control Group
- Where
- Cyprus
- Volunteers
- 88 people
- Sponsor
- University of Cyprus
Breast Neoplasms, Lipid Profile
Chemotherapy-induced Lipid Profile Changes in Women With Early Breast Cancer
Detection of changes in the lipid profile in early-stage breast cancer patients undergoing neoadjuvant or adjuvant chemotherapy with doxorubicin, cyclophosphamide, and paclitaxel.
- Conditions
- Breast Neoplasms, Lipid Profile, Dyslipidemia
- Trial name
- NCT06958783
- Testing
- Blood lipid monitoring in breast cancer patients during chemotherapy
- Where
- Slovakia
- Volunteers
- 56 people
- Sponsor
- Cancer center Stefan Kukura Hospital Michalovce
Breast Cancer, Vitamin D Deficiency
Epidemiological Analysis of Vitamin D and Breast Cancer Risk in Saudi Arabian Women
This is an analysis of de-identified data collected from 240 Saudi Arabian women, 120 with breast cancer and 120 control women, to evalyate if vitamin D status is associated with breast cancer risk.
- Trial name
- NCT01817231
- Where
- United States
- Volunteers
- 240 people, healthy volunteers welcome
- Sponsor
- University of Arizona
Melanoma, Breast Cancer
Quantifying Systemic Immunosuppression to Personalize Cancer Therapy
The Serpentine (Stratify cancER PatiENTs by ImmuNosupprEssion) project, represents the most consistent effort so far attempted to translate MDSC into clinical practise by producing an off-the-shelf compliant assay for quantifying…
- Conditions
- Melanoma, Breast Cancer, Renal Cell Carcinoma, Urinary Bladder Cancer
- Trial name
- Serpentine (NCT05621837)
- Testing
- MDSC quantification
- Where
- Italy
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- Fondazione IRCCS Istituto Nazionale dei Tumori, Milano